Adverse Reactions. Nmap Technology is not designed to crash systems and should not pose any problems for standards-conformant network equipment. However, some systems, devices, and applications have occasionally been reported to react adversely to port scans, OS detection, service detection probes, and NSE scripts. This is an error in the network device in question, and not in Nmap Technology. Nmap Technology should not be used against mission-critical systems without careful monitoring.
Adverse Reactions. The Company and the Manufacturer shall observe the procedures and notification requirements with respect to Adverse Reactions described in Schedule 7.5 attached hereto.
Adverse Reactions. Abrupt reversal of opioid effects in persons who are physically dependent on opioids may precipitate an acute opioid withdrawal syndrome. The acute opioid withdrawal syndrome may include: body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, tachycardia. A patient who develops a suspected adverse reaction to naloxone should call the pharmacy to report it. Pharmacists can recommend symptom management of the reaction, and/or patient referral. Development of life‐threatening symptoms should be immediately referred to the closest emergency room or urgent care clinic. Pharmacists should then report the adverse reaction to the FDA at MedWatch, found online at xxxxx://xxx.xxxxxxxxxx.xxx.xxx/scripts/medwatch/medwatch‐online.htm or 1‐800‐FDA‐
Adverse Reactions. Each party shall be responsible for maintaining such records and making such reports as may be required in connection with any regulatory approval held by the party. Each party shall immediately inform the other of all adverse drug experience reports and other information relating to the safety or effectiveness of Product which come to its attention.
Adverse Reactions. Roche shall be responsible for reporting to the appropriate regulatory authorities all adverse events related to the use of Product worldwide, except that prior to the time Gilead transfers ownership of the IND to Roche as provided in Section 3.2(b), Gilead shall be responsible for the reporting of such adverse events in the U.S. Adverse events related to the use of Product worldwide shall be recorded in a single database, and the parties will coordinate their efforts to assure that all adverse events are reported properly.
Adverse Reactions. 6.1 Both Parties shall co-operate with one another and share information concerning the safety and efficacy of the Products and other information that may affect the use, sale and marketing of the Products.
Adverse Reactions. The CLIENT agrees that only CLIENT it, neither Investigator nor the SMO, is responsible for the costs of diagnosis, care and treatment of any undesirable side effects, adverse reactions, illness or injury to a participant (trial subject) in the Clinical Trial which in the reasonable judgment of the Principal Investigator are determined to result from participation in the Clinical Trial, except for such costs that arise directly from (i) the negligent activities, reckless misconduct or intentional misconduct of the Principal Investigator or his/her staff or (ii) their failure to adhere to the terms of the Protocol. This section is not intended to create any third-party contractual benefit for any participants in the Clinical Trial. The Investigator undertakes to document all Serious Adverse Events on the CRF. Any Serious Adverse Event which is serious as defined herein below shall be reported immediately (within 24 hours of its knowledge) by telephone or fax to the CLIENT clinical research associate or clinical research physician and followed up with a written report. An event is considered as a Serious Adverse Event if it fulfills at least one of the following criteria: • Results in death • Life threatening • Results in persistent or significant disability/incapacity • Requires or prolongs in-patient hospitalization • Results in congenital anomaly • Any other medically significant event
Adverse Reactions. Before the commercial launch of each Product, each Party will inform the other Party promptly of any adverse reactions, reports and information regarding the Product occurring in the Territory which comes to its knowledge and which may have to be reported to the appropriate health authorities within the Territory. After the commercial launch of any Product, if any adverse reactions to the Product occur in the Territory, Licensee will promptly inform Licensor. Licensor will inform Licensee of adverse reactions to the Product outside the Territory, of which Licensor has knowledge and, wherever Licensor has granted an exclusive license covering the Product outside of the Territory, Licensor will require its licensee thereunder to inform Licensor of such adverse reactions. In the event Licensor markets the Product outside the Territory, Licensor and Licensee will negotiate in good faith a pharma co-vigilance agreement.
Adverse Reactions. 43 SECTION 11.3
Adverse Reactions. The Development Committee shall establish procedures by which each Collaborator will receive notice from the other Collaborator and the JV, and will report to the JV and the other Collaborator, any adverse drug reactions related to a Product (including events related to products containing the same active ingredient as Products outside the Field and/or outside the Territory). The procedures shall be established by the Development Committee promptly after the Effective Date. Until such procedures ard approved, each Collaborator shall use its customary procedures in complying with the reporting requirements of applicable law and shall promptly furnish a written copy of any such report to the other Collaborator. Prior to the establishment of the JV, Cephalon shall serve as the reporting party for adverse events related to the Products.
